Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus

Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Kevin R. Kelly1, Claudia M. Espitia2, Weiguo Zhao2, Erik Wendlandt3, Guido Tricot3, Fenghuang Zhan3, Jennifer S. Carew4, Steffan T. Nawrocki2 1Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA, USA 2Department of Medicine and The Institute for Drug Development, Cancer Therapy and Research Center at The University of Texas Health Science Center, San Antonio, TX, USA 3Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA 4Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA Correspondence to: Steffan T. Nawrocki, e-mail: Nawrocki@uthscsa.edu Keywords: myeloma, reovirus, bortezomib, JAM-A, NOXA Received: August 20, 2015 Accepted: October 05, 2015 Published: October 15, 2015